Published • loading... • Updated
Dyne Therapeutics stock rises on positive DM1 trial results
Summary by BizToc
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Dyne Therapeutics stock rises on positive DM1 trial results
Investing.com -- Dyne Therapeutics Inc (NASDAQ:DYN) shares gained 2.1% in after-hours trading Tuesday following the release of one-year trial data for its experimental DM1 treatment z-basivarsen. The clinical-stage biotechnology company reported functional improvement data from the multiple…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
